TGA grants provisional determination to Roche Products Pty Ltd COVID-19 treatment tocilizumab (ACTEMRA)
On 27 September 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the COVID-19 treatment tocilizumab (ACTEMRA).
Published
Related content
- TGA grants provisional determination to Celltrion Healthcare Australia Pty Ltd's antiviral COVID-19 treatment regdanvimabOn 20 August 2021 the TGA granted provisional determination to Celltrion Healthcare Australia Pty Ltd in relation to regdanvimab.
- TGA grants provisional determination to Roche Products Pty Ltd combination COVID-19 treatment casirivimab + imdevimab (RONAPREVE)On 20 August 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the combination therapy casirivimab + imdevimab (RONAPREVE)
- TGA grants provisional determination to Merck Sharp & Dohme's antiviral COVID-19 treatment MolnupiravirOn 9 August 2021 the TGA granted provisional determination to Merck Sharp & Dohme (Australia) Pty Ltd (MSD) in relation to Molnupiravir.